Retrospective Study Assessment Treatment Response Faslodex®( 500 mg)
NCT01509625
·
clinicaltrials.gov ↗
COMPLETED
Status
272
Enrollment
OTHER
Sponsor class
Conditions
Malignant Neoplasm of Breast Stage IV
Interventions
DRUG:
Fulvestrant
Sponsor
Isabel Blancas